AI assistant
Pharmanutra — Investor Presentation 2021
Nov 25, 2021
4324_rns_2021-11-25_3ecff8b6-909f-4ab6-a2be-721a99b8ed92.pdf
Investor Presentation
Open in viewerOpens in your device viewer
| Informazione Regolamentata n. 20106-60-2021 |
Data/Ora Ricezione 25 Novembre 2021 07:56:49 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 154553 | |
| Nome utilizzatore | : | PHARMANUTRAN02 - Lacorte Roberto | |
| Tipologia | : | REGEM | |
| Data/Ora Ricezione | : | 25 Novembre 2021 07:56:49 | |
| Data/Ora Inizio Diffusione presunta |
: | 25 Novembre 2021 07:56:50 | |
| Oggetto | : | PR - PHARMANUTRA - THREE NEW PATENTS RELEASED |
|
| Testo del comunicato |
Vedi allegato.
PHARMANUTRA GROUP: THREE NEW PATENTS RELEASED
PharmaNutra S.p.A. has been granted the patent for cetylated fatty acids (CFA) on Russian territory and its subsidiary Alesco S.r.l. two new patents in Italy.
Pisa, 25 November 2021 – PharmaNutra S.p.A. (MTA; Ticket PHN), a group of companies specialising in the development, production and distribution of raw materials (active ingredients) for the pharmaceuticals and nutraceuticals market, has been granted two new patents by the Italian Patents & Trademarks Office for its subsidiary Alesco S.r.l. and one new patent by the Russian Federal Agency for Intellectual Property for PharmaNutra S.p.A.
The first Italian patent (no. 102019000022989) is for Sucrosomial® Chromium (UltraChrome™ ), a brand new functional ingredient. Chromium is a microelement that regulates energy metabolism and helps maintaining the normal glucose levels in blood. The application of Sucrosomial® Technology guarantees improved tolerability and absorption, allowing its use in solutions for blood cholesterol and glucose control.
The second patent issued to Alesco S.r.l. (no. 102019000023016) is for the production, composition and use of new mineral-polysaccharide combinations for mineral supplements. This represents a further upgrade of Sucrosomial® Technology, which enables development of new solutions and technologies to increase the absorption and tolerability of nutrients.
"Scientific research has always been the driving force in PharmaNutra and these three new patents confirm this attitude," said Group Chairman Andrea Lacorte. "These important upgrades of Sucrosomial® Technology offer significant potential and strong medium/long-term development prospects. I'm sure the market will acknowledge the value of these new assets, developed thanks to our Scientific Department and our inclination toward innovation."
Moreover, PharmaNutra has obtained from the Russian Federal Agency for Intellectual Property a patent for the production and use of Cetylated Fatty Acids (CFA), the functional ingredient at the base of all Cetilar® products. After India and China, the Russian Federation now joins the list, further broadening and consolidating the Group's international development.
PharmaNutra S.p.A.
Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology, and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies and parapharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.
For further information:
Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]